U.S. Markets closed
  • S&P Futures

    3,269.00
    -6.00 (-0.18%)
     
  • Dow Futures

    27,008.00
    -47.00 (-0.17%)
     
  • Nasdaq Futures

    10,951.75
    -37.25 (-0.34%)
     
  • Russell 2000 Futures

    1,478.80
    -4.00 (-0.27%)
     
  • Crude Oil

    39.57
    +0.26 (+0.66%)
     
  • Gold

    1,913.50
    +2.90 (+0.15%)
     
  • Silver

    24.70
    +0.32 (+1.30%)
     
  • EUR/USD

    1.1766
    -0.0007 (-0.0588%)
     
  • 10-Yr Bond

    0.6710
    -0.0230 (-3.31%)
     
  • Vix

    27.78
    +1.95 (+7.55%)
     
  • GBP/USD

    1.2815
    -0.0002 (-0.0154%)
     
  • BTC-USD

    10,474.25
    +36.52 (+0.35%)
     
  • CMC Crypto 200

    222.33
    -13.25 (-5.62%)
     
  • FTSE 100

    5,804.29
    -202.76 (-3.38%)
     
  • Nikkei 225

    23,360.30
    +40.90 (+0.18%)
     

RELX Opens Bioscience Lab to Enhance Global E-Cigarette Research

RELX Technology today announced the company has started operations at its newly-established e-cigarette bioscience laboratory to conduct systematic research on the effects of e-cigarettes through in vivo and in vitro tests, as well as conduct pre-clinical safety assessments.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200917005346/en/

RELX Technology announced the company has started operations at its newly-established e-cigarette bioscience laboratory (Photo: Business Wire)

The bioscience laboratory, located in International Bioindustry Valley, Shenzhen is currently conducting research on the impact of RELX products on animal cardiovascular, respiratory, and nervous systems, in order to better carry out a comprehensive impact evaluation of vapor products.

"Science is the foundation of trust. As the industry leader, we have the responsibility to expand the borders of e-cigarette science and explore the unknown," said Kate Wang, founder and CEO of RELX.

At the RELX Lab Open Day, RELX also announced its plan to establish a "1+4" scientific research approach—i.e. anchored by Platform Development, followed by Toxicological Assessment, Clinical Assessment, Perception Behavior Study and Long Term Assessment.

According to Public Health England, e-cigarettes are 95% less harmful to health than smoking and have the potential to help smokers quit smoking. Many consumers have recognized e-cigarettes as a better alternative to traditional combustible cigarettes.

There are still many areas that require further long-term research, such as the actual harm reduction elements of e-cigarettes, the maximization of their harm reduction, and other potential effects of vaping.

"E-cigarettes are sometimes viewed with suspicion because we have incomplete knowledge," said Yilong Wen, RELX Co-founder and Head of Science, Research and Development and Supply Chain, "The RELX bioscience lab’s mission is to explore the unknown. We want to collect evidence through a scientific approach and strive to prove the potential for e-cigarettes to be less harmful, and in doing so, provide users the option to choose an alternative.

To ensure the reliability and quality of RELX products, RELX established a chemical and physical laboratory in 2018. The laboratory is certified by the internationally recognized China National Accreditation Service for Conformity Assessment. RELX started its groundbreaking research on the toxicological and pharmacological study on its products in 2019, and the new bioscience lab will focus on vivo and in vitro tests, as well as conduct pre-clinical safety assessments in 2020.

"The toxicological and pharmacological studies focus on the effects of RELX’s products," said Xingtao Jiang, Head of RELX Lab, "For example, does it affect DNA or chromosomes, and what are the ingredients’ long-term impact on body organs and tissues? There is still a lot of research to be done."

Xingtao Jiang also announced five preliminary findings from RELX’s research so far. Among these were that according to the data, the levels of harmful substances such as benzene and four TSNAs (Tobacco-specific N-nitrosoamines) emitted by RELX products are lower than those found in combustible cigarette smoke by over 99.1 percent and 99.8 percent respectively.

RELX is currently conducting research projects on different topics with six universities including the Sun Yat-sen University and Shenzhen Institutes of Advanced Technology, the Chinese Academy of Sciences, two hospitals and nine scientific research institutions.

ABOUT RELX Technology

Founded in January 2018, RELX is Asia’s leading e-cigarette brand. RELX independently develops its e-cigarette products at its R&D center in Shenzhen, China. RELX’s mission is to empower adult smokers through technology, product and science, ethically. RELX continues to make significant investments in R&D, e-liquid testing and new product development. The company has attracted global talents from Uber, Proctor and Gamble, Huawei, Beats, and L’Oréal. RELX investors include top venture capital firms Source Code Capital, IDG Capital, and Sequoia Capital.

Website: https://relxnow.com
Twitter: @Relxtech
Facebook: @Relxnow
Instagram: relxtech
Linkedin: RELX Technology

View source version on businesswire.com: https://www.businesswire.com/news/home/20200917005346/en/

Contacts

Yasha Wolfman
yasha.wolfman@relxtech.com

Aimee Ren
aimee.ren@relxtech.com